ARV-based HIV prevention for women - where we are in 2014
- PMID: 25224614
- PMCID: PMC4164013
- DOI: 10.7448/IAS.17.3.19154
ARV-based HIV prevention for women - where we are in 2014
Abstract
Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention - TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level.
Keywords: AIDS; HIV; HIV prevention; HIV treatment; PrEP; antiretroviral agents; women.
Similar articles
-
Women and ARV-based HIV prevention - challenges and opportunities.J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19356. doi: 10.7448/IAS.17.3.19356. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25224621 Free PMC article.
-
Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19146. doi: 10.7448/IAS.17.3.19146. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25224610 Free PMC article. Clinical Trial.
-
Communicating about microbicides with women in mind: tailoring messages for specific audiences.J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19151. doi: 10.7448/IAS.17.3.19151. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25224612 Free PMC article.
-
Antiretroviral Medications for the Prevention of HIV Infection: A Clinical Approach to Preexposure Prophylaxis, Postexposure Prophylaxis, and Treatment as Prevention.Infect Dis Clin North Am. 2019 Sep;33(3):629-646. doi: 10.1016/j.idc.2019.04.002. Epub 2019 Jun 22. Infect Dis Clin North Am. 2019. PMID: 31239092 Review.
-
Update on HIV Chemoprevention.Annu Rev Med. 2025 Jan;76(1):43-56. doi: 10.1146/annurev-med-042823-013707. Annu Rev Med. 2025. PMID: 39869431 Review.
Cited by
-
Women and ARV-based HIV prevention - challenges and opportunities.J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19356. doi: 10.7448/IAS.17.3.19356. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25224621 Free PMC article.
-
Adaptation and validation of simple tools to screen and monitor for oral PrEP adherence.PLoS One. 2021 May 27;16(5):e0251823. doi: 10.1371/journal.pone.0251823. eCollection 2021. PLoS One. 2021. PMID: 34043657 Free PMC article.
-
The impact of socioeconomic factors on the healthcare costs of people living with HIV in Turkey.BMC Public Health. 2020 Mar 20;20(1):368. doi: 10.1186/s12889-020-08469-z. BMC Public Health. 2020. PMID: 32197598 Free PMC article.
-
New prospects for a preventive HIV-1 vaccine.J Virus Erad. 2015 Apr;1(2):78-88. J Virus Erad. 2015. PMID: 26523292 Free PMC article.
-
Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.Int J Pharm. 2017 Oct 5;531(1):118-133. doi: 10.1016/j.ijpharm.2017.08.061. Epub 2017 Aug 7. Int J Pharm. 2017. PMID: 28797967 Free PMC article.
References
-
- Joint United Nations Programme on HIV/AIDS (UNAIDS) Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS; 2013.
-
- Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabilito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtriciabine, or vaginal tenofovir gel in the VOICE study (MTN 003); Conference on Retroviruses and Opportunistic Infections (CROI); 2013 Mar 3–6; Atlanta, GA.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous